Cardio-vascular
Refine Search
Pharmaceutical
Following action last month by both European and US regulators after the discovery of an impurity in certain medicines containing the blood pressure drug valsartan, the European Medicines Agency has issued its preliminary assessment of possible risks to patients. 3 August 2018
Pharmaceutical
Family-owned German drugmaker Boehringer Ingelheim has issued a statement related to its financial performance in 2018, indicating the firm achieved “modest growth,” with net revenues of 8.6 billion euros ($10 billion). 1 August 2018
Pharmaceutical
US pharma giant Pfizer has lowered its estimate for total 2018 revenues in presenting its second quarter financial results. 31 July 2018
Pharmaceutical
From August 1, patients in New Zealand will have access to German pharma major Bayer’s oral anticoagulant Xarelto (rivaroxaban), used for preventing stroke and treating or preventing blood clots. 30 July 2018
Pharmaceutical
The strategy pursued by Pascal Soriot since he took over as AstraZeneca chief executive in 2012 – of investing massively in R&D in the hope of replacing revenues lost through expiring patents – has arguably been one of the bravest in pharma. 26 July 2018
Pharmaceutical
The UK’s AstraZeneca has agreed a $200 million-plus deal to out-license rights to cardiovascular therapies Atacand (candesartan cilexetil) and Atacand Plus (candesartan cilexetil/hydrochlorothiazide). 24 July 2018
Generics
On Friday, the US Food and Drug Administration alerted health care professionals and patients of a voluntary recall of several drug products containing the active ingredient valsartan, used to treat high blood pressure and heart failure. 16 July 2018
Generics
The European Medicines Agency (EMA) is reviewing medicines containing the active substance valsartan that is supplied by Zhejiang Huahai Pharmaceuticals, a company based in Linhai, China. 6 July 2018
Pharmaceutical
German pharma major Bayer has announced a new chapter in its partnership with US research center The Broad Institute of MIT and Harvard. 2 July 2018
Pharmaceutical
Shares in cardiometabolic disorders specialist Gemphire Therapeutics nearly doubled in value on Friday following encouraging results from a Phase IIb trial of gemcabene. 2 July 2018
Pharmaceutical
Singapore-based Menarini Asia-Pacific Holdings and Japanese pharma major Daiichi Sankyo (TYO: 4568) have signed a multi-year exclusive licensing agreement for the former to assume the sales, marketing and distribution of the oral, once-daily, direct factor Xa inhibitor anticoagulant Lixiana (edoxaban) in the Philippines, Malaysia and Singapore, following respective regulatory approvals in those countries. 29 June 2018
Pharmaceutical
Privately-held Boehringer Ingelheim and its partner Eli Lilly have added to the case for their drug Jardiance (empagliflozin) at the American Diabetes Association Scientific Sessions. 25 June 2018
Biotechnology
Amgen has announced new data that show Repatha (evolocumab) significantly reduced low-density lipoprotein cholesterol (LDL-C) and non-high density lipoprotein cholesterol (non-HDL-C) in patients with type 2 diabetes and hypercholesterolemia or mixed dyslipidemia, taking the maximum tolerated dose of moderate/high-intensity statin therapy. 25 June 2018
Pharmaceutical
US biopharma company CASI Pharmaceuticals has announced a strategic and long-term manufacturing agreement with Yiling Wanzhou International Pharmaceutical for the manufacturing of entecavir and cilostazol. 21 June 2018
Pharmaceutical
Florida, USA-based Nutriband (OTCQB: NTRB), has signed a Letter of Intent to acquire 100% of Carmel Biosciences, a pharmaceutical company that addresses critical needs in new drug and liquid reformulation for cardiovascular and metabolic therapies. 14 June 2018
Biotechnology
US biotech firm Biogen has turned to a Japanese company’s research as it looks to develop a new stroke drug. 7 June 2018
Pharmaceutical
Japanese pharma major Daiichi Sankyo today announced that more than 97% of eligible claimants have opted into the product liability litigation settlement program announced on March 30, 2018 for cases brought against various Daiichi Sankyo and Forest entities. 6 June 2018
Biotechnology
South Korean company Celltrion Healthcare is already proving itself to be one of the leaders globally in biosimilar drug development, but a new deal is a sign of its potential as a developer of new biopharmaceuticals. 1 June 2018
Pharmaceutical
While the financial damage from a court settlement announced on Thursday will barely cause a ripple at US drug giant Pfizer, the reputational damage for paying illegal kickbacks could be more noticeable. 25 May 2018
Biotechnology
US clinical and commercial manufacturing of therapeutic proteins company AGC Biologics, says that it will supply bulk drug substance for the launch of AndexXa (coagulation factor Xa [recombinant], inactivated-zhzo), the first and only antidote indicated for patients treated with rivaroxaban and apixaban, when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding. 25 May 2018
Biotechnology
Dutch clinical-stage biotech NewAmsterdam Pharma, which is focused on non-statin medicines for patients at risk of cardiovascular disease (CVD), has announced positive top-line data from its Phase III TANDEM clinical trial. 21 November 2024
Biotechnology
US biotech major Amgen has announced that Dr Howard Chang will join the company as senior vice president of research, effective December 16, 2024. 21 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Anthos Therapeutics has presented data at the American Heart Association (AHA) Scientific Sessions from its landmark AZALEA-TIMI 71 study showing that abelacimab led to consistent and substantial reductions in bleeding for patients on or off antiplatelet (APT) therapy, compared to rivaroxaban. 18 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Pharmaceutical
The US Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for donidalorsen, an investigational RNA-targeted medicine for prophylaxis to prevent attacks of hereditary angioedema (HAE) in adult and pediatric patients 12 years of age and older, under development by Ionis Pharmaceuticals. 4 November 2024
Biotechnology
Ascendis Pharma has granted fellow Denmark-based Novo Nordisk an exclusive worldwide license to the TransCon technology platform to develop, manufacture and commercialize Novo Nordisk proprietary products in metabolic diseases (including obesity and type 2 diabetes) and a product-by-product exclusive license in cardiovascular diseases. 4 November 2024
Pharmaceutical
Swiss pharma giant Novartis revealed rising sales and earnings in its third-quarter financial results on Tuesday. 29 October 2024
Pharmaceutical
Denmark-based Novo Nordisk’s oral semaglutide, marketed as Rybelsus for type 2 diabetes, has not gained much presence in the GLP-1 receptor agonists (GLP-1RAs) market despite its approval in 2019, as its injectable alternatives prove to have higher efficacy and results both in diabetes and obesity patients. 28 October 2024
Pharmaceutical
Germany’s Bayer has entered into an exclusive licensing agreement with privately-held Dewpoint Therapeutics for a heart disease program to treat dilated cardiomyopathy (DCM) patients, who are characterized through carrying specific mutations. 25 October 2024
Pharmaceutical
Philadelphia, USA-based SERB Pharmaceuticals has announced the acquisition of Aurlumyn (iloprost), the only FDA-approved treatment for severe frostbite in the USA. 22 October 2024
Pharmaceutical
The Institute for Clinical and Economic Review (ICER) has released its final report assessing the effectiveness and pricing of key treatments for transthyretin amyloid cardiomyopathy (ATTR-CM). 22 October 2024
Pharmaceutical
Novo Nordisk today announced the headline results from the SOUL cardiovascular outcomes trial. The double-blinded, randomized trial compared oral semaglutide to placebo as an adjunct to standard of care for the prevention of major adverse cardiovascular events (MACE). 21 October 2024
Generics
Lexicon Pharmaceuticals announced that Viatris has obtained an exclusive license from Lexicon to commercialize sotagliflozin outside of the USA and Europe in all indications. 18 October 2024
Pharmaceutical
Johnson & Johnson has reported revenue of $22.5 billion for the third quarter of 2024, a 5.2% increase year-over-year. 15 October 2024
Generics
Two US units of Israel’s Teva Pharmaceutical Industries have agreed to pay $450 million to resolve two matters that allege Teva violated the Anti-Kickback Statute (AKS) and the False Claims Act (FCA), the US Department of Justice (DoJ) announced yesterday. 11 October 2024
Pharmaceutical
Cardiopulmonary diseases specialist Liquidia Corporation closed Monday’s trading 11% higher following a favorable court ruling. 8 October 2024
Pharmaceutical
AstraZeneca has entered into an exclusive license agreement with China’s CSPC Pharmaceutical to advance the development of an early stage, novel small molecule lipoprotein (a) (Lp(a)) disruptor that has the potential to offer additional benefits for patients with dyslipidemia. 7 October 2024
Pharmaceutical
Privately-held metabolic health specialist Rivus Pharmaceuticals has announced new clinical data from the Phase IIa HuMAIN study of HU6 in patients with obesity-related heart failure with preserved ejection fraction (HFpEF) 1 October 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze